Head to Head Comparison: Tyra Biosciences (NASDAQ:TYRA) versus Zoetis (NYSE:ZTS)

Tyra Biosciences (NASDAQ:TYRA – Get Rating) and Zoetis (NYSE:ZTS – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Valuation and Earnings

This table compares Tyra Biosciences and Zoetis’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$55.33 million	($1.25)	-11.16
Zoetis	$8.08 billion	9.42	$2.11 billion	$4.43	37.19

Zoetis has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Tyra Biosciences has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

Insider and Institutional Ownership

84.6% of Tyra Biosciences shares are held by institutional investors. Comparatively, 90.2% of Zoetis shares are held by institutional investors. 18.4% of Tyra Biosciences shares are held by company insiders. Comparatively, 0.1% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Tyra Biosciences and Zoetis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-19.89%	-19.32%
Zoetis	25.59%	50.26%	16.24%

Analyst Recommendations

This is a summary of recent ratings for Tyra Biosciences and Zoetis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	0	0	2	0	3.00
Zoetis	0	0	8	0	3.00

Tyra Biosciences presently has a consensus target price of $21.00, suggesting a potential upside of 50.54%. Zoetis has a consensus target price of $221.14, suggesting a potential upside of 34.24%. Given Tyra Biosciences’ higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than Zoetis.

Summary

Zoetis beats Tyra Biosciences on 9 of the 12 factors compared between the two stocks.

About Tyra Biosciences

(Get Rating)

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

About Zoetis

(Get Rating)

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S. market and regulatory activities. The International segment includes non-U.S. market and regulatory activities. The company was founded in 1952 and is headquartered in Parsippany, NJ.